Hypoxia induced mitogenic factor

Details Hypoxia induced mitogenic factor Hypoxia induced mitogenic factor

2010-02-02

2011-12-20

Gibbs, Terra Cotta (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

08080533

ABSTRACT:
We found that FIZZ1/RELMα is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELMα was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELMα protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.

REFERENCES:
patent: 2002/0142982 (2002-10-01), Hla et al.
patent: 98-58061 (1998-12-01), None
patent: 99-55868 (1999-11-01), None
patent: 00-04923 (2000-02-01), None
patent: 00-53760 (2000-09-01), None
Angelini et al. (Am. J. Physiol. Lung Cell Mol. Physiol, 2009 vol. 296:6582-L593).
International Search Report for International Application No. 504/03875, mailed Aug. 31, 2007.
Branch, AD. TIBS, 1998 vol. 23:45-50.
Downward, J. Science, medicine, and the future. RNA interference. BMJ, 2004 vol. 328:1245-1248.
Lu et al. (2005). Delivering siRNA in vivio for functional genomics and novel therapeutics. From RNA Interference Technology (Cambridge, Appasani, ed., pp. 303-317).
Samarsky et al. (2005). RNAi in drug development: Practical considerations. From RNA Intereference Technology (Cambridge, Appasani, ed., pp. 384-395).
Agrawal et al. Molecular Medicine Today, 2000 vol. 6:72-81.
Chalk et al. Center for Genomics and Bioninformatics, Karolinksa Intitutet. Computational antisense oligo prediction with a neural network model. Dec. 2002. vol. 18:1567-1575.
Ding et al. Nucleic Acids Research. Statistical prediction of single-stranded regions in RNA secondary structure and application to predicting effective antisense target sites and beyond. 2001, vol. 29, No. 5, pp. 1034-1046.
Lehmann et al. Nucleic Acids Research. Theoretical design of antisense genes with statistically increased efficacy. 2000. vol. 28, No. 13, pp. 2597-2604.
Rychahou et al. Department of Surgery and the Sealy Center for Cancer Cell Biology, RNA interference: Mechanisms of action and therapeutic consideration. Nov. 2006. vol. 140, No. 5, pp. 719-725.
Ma et al. American Journal of Respiratory Cell and Molecular Biology, Lipid-Mediated Delivery of Oligonucleotide to Pulminary Endothelium. 2002. vol. 27:151-159.
Metzger et al. Respirable Antisense Oligonucleotide (RASON) Therapy for Allergic Asthma. BioDrug Oct. 1999; 12 (4): 237-243.

Affiliated with

Also associated with

Rating

Hypoxia induced mitogenic factor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hypoxia induced mitogenic factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hypoxia induced mitogenic factor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4316618